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Summary
Background Helminth infections aﬀ ect the human immune response. We investigated whether prenatal exposure 
to and treatment of maternal helminth infections aﬀ ects development of an infant’s immune response to 
immunisations and unrelated infections.
Methods In this randomised, double-blind, placebo-controlled trial, we enrolled 2507 women in the second or third 
trimester of pregnancy who were planning to deliver in Entebbe General Hospital, Entebbe, Uganda. With a computer-
generated random number sequence in blocks of 100, we assigned patients to 440 mg albendazole and 40 mg/kg 
praziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziquantel and 
an albendazole-matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching placebo 
(n=628). All participants and hospital staﬀ  were masked to allocation. Primary outcomes were immune response at 
age 1 year to BCG, tetanus, and measles immunisation; incidence of infectious diseases during infancy; and vertical 
HIV transmission. Analysis was by intention-to-treat. This trial is registered, number ISRCTN32849447.
Findings Data were available at delivery for 2356 women, with 2345 livebirths; 2115 (90%) of liveborn infants remained 
in follow-up at 1 year of age. Neither albendazole nor praziquantel treatments aﬀ ected infant response to BCG, 
tetanus, or measles immunisation. However, in infants of mothers with hookworm infection, albendazole treatment 
reduced interleukin-5 (geometric mean ratio 0·50, 95% CI 0·30–0·81, interaction p=0·02) and interleukin-13 (0·52, 
0·34–0·82, 0·0005) response to tetanus toxoid. The rate per 100 person-years of malaria was 40·9 (95% CI 38·3–43·7), 
of diarrhoea was 134·1 (129·2–139·2), and of pneumonia was 22·3 (20·4–24·4). We noted no eﬀ ect on infectious 
disease incidence for albendazole treatment (malaria [hazard ratio 0·95, 95% CI 0·79–1.14], diarrhoea [1·06, 
0·96–1·16], pneumonia [1·11, 0·90–1·38]) or praziquantel treatment (malaria [1·00, 0·84–1·20], diarrhoea [1·07, 
0·98–1·18], pneumonia [1·00, 0·80–1·24]). In HIV-exposed infants, 39 (18%) were infected at 6 weeks; vertical 
transmission was not associated with albendazole (odds ratio 0·70, 95% CI 0·35–1·42) or praziquantel (0·60, 
0·29–1·23) treatment.
Interpretation These results do not accord with the recently advocated policy of routine antenatal anthelmintic 
treatment, and the value of such a policy may need to be reviewed. 
Funding Wellcome Trust.
Introduction
Worldwide, infectious diseases account for more than 
50% of deaths of children younger than 5 years; 
pneumonia, diarrhoeal disease, and malaria are the three 
most common causes.1 More than half of these deaths 
occur in sub-Saharan Africa, where roughly 2·5 million 
children younger than 5 years are estimated to die every 
year from one of these three diseases. Immunisation is a 
key strategy to combat infectious diseases, but 
immunisation programmes in developing countries vary 
in eﬀ ectiveness.2 For example, increases in measles 
immunisation coverage have led to substantial falls in 
the incidence of measles;3 by contrast, despite high 
immunisation coverage, the prevalence of tuberculosis is 
high in sub-Saharan Africa, and is one of the leading 
causes of deaths in adults.4 BCG is the only available 
vaccine against tuberculosis and its eﬀ ectiveness is 
lowest in countries closest to the equator.5,6 Soil-
transmitted helminth infections and schistosomiasis are 
also prevalent in developing countries,7 and their 
geographical distribution has extensive overlap with 
areas in which rates of infectious diseases are highest 
and the eﬀ ectiveness of BCG immunisation is lowest.8,9 
Such overlap in disease distributions has led to the 
suggestion that chronic helminth infections could aﬀ ect 
the epidemiological patterns of other diseases,10 through 
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impairment of immune responses to immunisations and 
unrelated infections.
This hypothesis was supported by the ﬁ nding that 
T-helper-1 (Th1) cell responses (characterised by 
interferon-γ production, induced by viral and bacterial 
antigens, and required for protection against mycobacteria 
and other intracellular pathogens) and T-helper-2 (Th2) 
cell responses (characterised by production of 
interleukins 4, 5, and 13 and induced by allergens such as 
helminth antigens) are mutually inhibitory.11–13 However, 
helminth infections induce immunoregulation by various 
other mechanisms, such as interleukin-10 production, 
and aﬀ ect responses to non-helminth antigens.14 Thus 
helminth infections could inhibit protective Th1 
responses to unrelated organisms, such as viruses, 
bacteria, and vaccines, by inducing a Th1 to Th2 switch 
and through immunoregulatory mechanisms. Several 
studies of animals and human beings lend support to 
this hypothesis.14 Although helminth infections are 
generally thought to have detrimental eﬀ ects on host 
responses to infectious pathogens, a beneﬁ cial eﬀ ect 
against other diseases is also possible through 
suppression of pathological inﬂ ammatory responses; 
some researchers have suggested an inverse association 
between helminth infections and incidence of severe 
malaria.15
Helminth infections are rare in infancy, when 
immunisations are given and many infectious disease-
related deaths occur. However, evidence exists that 
prenatal exposure to maternal helminth infection could 
have important eﬀ ects on an infant’s immune response. 
Prenatal sensitisation to Wuchereria bancrofti, a ﬁ larial 
worm, is associated with increased susceptibility to 
W bancrofti infection in childhood,16 and prenatal 
sensitisation to ﬁ larial or schistosome antigens with 
reduced Th1 and increased Th2 cytokine responses to 
mycobacterial antigens after BCG immunisation at 
birth.2,17 Such ﬁ ndings suggest that prenatal exposure to 
maternal helminth infection modulates an infant’s 
immune response to vaccination and infectious 
pathogens, and that anthelmintic treatment during 
pregnancy can prevent these eﬀ ects. We designed this 
trial of anthelmintic treatment during pregnancy to 
address this hypothesis. We also examined eﬀ ects of 
anthelmintic treatment during pregnancy on infant 
mortality, and on anaemia and growth at age 1 year, to 
assess the overall risks and beneﬁ ts of anthelmintic 
treatment during pregnancy.
Methods
Study design and patients
The study is described in detail elsewhere.18 Brieﬂ y, the 
study area was Entebbe Municipality and Katabi 
subcounty, beside Lake Victoria, Uganda. The area is 
occupied by urban, rural, and ﬁ shing communities. 
Helminth infection is highly prevalent in the area,19 and 
malaria, diarrhoea, and pneumonia are common in 
young children.20 The study population consisted of 
pregnant women who presented at the government-
funded antenatal clinic at Entebbe General Hospital 
between April 9, 2003, and Nov 24, 2005, where roughly 
70% of pregnant women from the study area received 
antenatal care.21 Women were included if resident in the 
study area, planning to deliver in the hospital, willing to 
know their HIV status, and in the second or third 
trimester of pregnancy. They were excluded if they had 
possible helminth-induced pathological changes 
(haemoglobin <80 g/L, clinically apparent severe liver 
disease, or diarrhoea with blood in stool), a history of an 
adverse reaction to anthelmintics, already been enrolled 
in the trial during an earlier pregnancy, or if the pregnancy 
was deemed abnormal by a midwife.
All participants gave written, informed consent. Ethics 
approval was given by the Uganda Virus Research 
Institute, Uganda National Council for Science and 
Technology, and London School of Hygiene and Tropical 
Medicine. 
Randomisation and masking
We used a two-by-two factorial design to randomly assign 
patients in a 1:1:1:1 ratio to receive simultaneously either 
single-dose albendazole (440 mg) and single-dose 
praziquantel (40 mg/kg), albendazole and a praziquantel-
matching placebo, an albendazole-matching placebo and 
praziquantel, or an albendazole-matching placebo and 
a praziquantel-matching placebo (albendazole and 
matching placebo, Glaxosmithkline, Brentford, UK; 
praziquantel and matching placebo, Medochemie Ltd, 
Limassal, Cyprus). The randomisation code was 
generated by the trial statistician with a computer-
generated random number sequence, with block size 100. 
Treatments were packed in sealed envelopes and labelled 
with an allocation number by colleagues at the Medical 
Research Council Unit in Entebbe who did not otherwise 
contribute to the trial. Treatments were allocated in 
numerical order by trained interviewer-counsellors who 
observed the patients taking the treatment correctly on 
enrolment to the study. Treatment allocation was masked 
from all participants and staﬀ  during the study.
Procedures
Demographic and clinical details, and blood samples 
were obtained at screening; stool samples were obtained 
before enrolment. After enrolment, women continued to 
receive standard antenatal care, including haematinics, 
tetanus immunisation, and intermittent presumptive 
treatment for malaria twice after their ﬁ rst trimester of 
pregnancy; women with HIV were oﬀ ered intrapartum 
and neonatal single-dose nevirapine for prevention of 
mother-to-child (vertical) HIV transmission.22 Stool 
samples were obtained after delivery to assess 
eﬀ ectiveness of anthelmintic treatment; thereafter, all 
mothers received praziquantel and albendazole. Infants 
received BCG and polio immunisation at birth; 
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diphtheria, pertussis, tetanus, Haemophilus inﬂ uenzae, 
hepatitis B, and polio immunisation at 6, 10, and 14 weeks; 
and measles immunisation at 9 months. Children also 
attended the study clinic when unwell; doctors diagnosed, 
treated, and recorded their illnesses. Community 
ﬁ eldworkers visited each participant’s home twice a 
month, measured the child’s temperature, and recorded 
symptoms reported by the child’s carer. At age 12 months, 
blood and stool samples were obtained from the children 
and growth outcomes were measured. Children who 
were unwell at their 12-month visit were given appropriate 
treatment and asked to return to complete the visit 
procedures when well.
The primary outcomes were immune response at age 
1 year to BCG, tetanus, and measles immunisation; 
incidence of malaria, diarrhoea, pneumonia, measles, 
and tuberculosis during infancy as diagnosed by doctors 
at the study clinic; and vertical HIV transmission.18 
Planned secondary outcomes were growth and anaemia 
at age 1 year. Community-reported data for illness events 
were included as a secondary outcome for comparison 
with doctor-diagnosed illness events from clinic visits. 
We also considered two additional unplanned secondary 
outcomes: infant mortality and asymptomatic malaria 
(presence of malaria parasitaemia) at 1 year of age.
Cytokine responses at 1 year of age to crude culture 
ﬁ ltrate proteins of Mycobacterium tuberculosis (cCFP) were 
measured as an indicator of response to BCG 
immunisation. Cytokine responses at age 1 year to tetanus 
toxoid were measured as an indicator of response to 
tetanus immunisation. We examined stimulated 
interferon-γ (type 1), interleukin-5 (type 2), 
interleukin-13 (type 2), and interleukin-10 (regulatory) 
responses in a whole-blood assay, as previously described.23 
Total serum IgG, IgG4, and IgE responses to tetanus 
toxoid were measured by ELISA (webappendix p 1). 
Total serum measles-speciﬁ c IgG was measured by 
ELISA (Dade Behring/Siemens, Eschborn, Germany) 
according to the manufacturer’s protocol. Immunological 
assays were done after all samples had been obtained, in 
a randomised sequence (by use of a computer-generated 
random number sequence), to avoid confounding of 
secular trends with variations in assay performance.
For the primary outcome, doctor-diagnosed illness 
events, clinical malaria was fever (temperature ≥37·5°C) 
with parasitaemia; diarrhoea was an infant’s carer’s 
deﬁ nition, with stool frequency recorded;24 pneumonia 
was cough with diﬃ  culty in breathing, and age-speciﬁ c 
fast breathing;25 measles was deﬁ ned by standard clinical 
criteria and conﬁ rmed by measurement of speciﬁ c 
antibody;26 and children with suspected tuberculosis were 
investigated as clinically indicated.27 For the secondary 
outcome, community-reported illnesses, febrile illness 
was deﬁ ned as measured by ﬁ eldworkers (temperature 
≥37·5°C) or as reported by the child’s carer; diarrhoea as 
reported by the carer, with stool frequency recorded; 
presumptive pneumonia was cough with diﬃ  culty in 
breathing, or age-speciﬁ c fast breathing as measured by 
ﬁ eldworkers.
Stool samples were examined for helminth ova with 
the Kato-Katz method28 and by charcoal culture for 
Strongyloides sterocoralis infection;29 two Kato-Katz slides 
were prepared from each sample and examined for 
hookworm ova within 30 mins of preparation, or 
examined the next day for other species. Hookworm and 
Schistosoma mansoni infections were classiﬁ ed into low, 
medium, and high intensities according to WHO 
guidelines.30 Blood samples were examined by a modiﬁ ed 
Knott’s method for Mansonella perstans31 and by thick ﬁ lm 
for malaria parasites. Haemoglobin was estimated by 
Coulter analyser (Beckman Coulter, Nyon, Switzerland). 
Quality control for Kato-Katz analyses was provided by 
the Vector Control Programme of the Ministry of Health, 
Uganda, and for haematology and malaria parasitology 
through the UK National External Quality Assessment 
Schemes.
Mothers’ HIV serology was done by rapid test 
algorithm.30 Blood was obtained from cord and at 6 weeks 
of age from infants of mothers with HIV for assessment 
of vertical HIV transmission. Plasma and whole blood 
cell pellet were separated by centrifugation and stored at 
–80°C until assays were done. For detection of HIV-1 
proviral DNA in infants at 6 weeks, DNA was extracted 
from stored whole blood cell pellets and ampliﬁ ed by 
nested PCR of three conserved viral regions, tat, gp41, 
and nef (webappendix p 1). For both cord and 6-week 
samples, plasma HIV load was measured with Bayer 
Versant branched DNA assay version 3.0 (Bayer, 
Leverkusen, Germany) or Roche Amplicor HIV-1 RNA 
Monitor test version 1.5 (Roche, NJ, USA).
Infants were regarded as being HIV positive if the 
6-week sample had a positive DNA PCR for any of the 
viral regions and a viral load of 1000 copies per mL or 
more; for four infants, only viral load data were available, 
so they were used to establish HIV status. Viral load and 
DNA-PCR results were concordant apart from one infant 
(viral load 6699 copies per mL, PCR negative) who was 
seronegative by rapid test algorithm at age 18 months 
and was classiﬁ ed as HIV negative. In infants with HIV 
infection, transmission was regarded as likely to have 
been intrauterine if the viral load in cord blood was 
1000 copies per mL or more.
Statistical analysis
Analysis was done after all children were older than 
15 months. Data for samples and measurements 
obtained at routine, 1-year visits were included if the 
child attended within 2 months after their ﬁ rst birthday. 
Data for illness events and mortality were censored 
strictly at 1 year. Results for younger twins were excluded 
from all analyses.
On the basis of our preliminary study,32 the planned 
cohort size of 2500 was expected to accrue 1860 person-
years of follow-up in infancy and 1594 infants were 
See Online for webappendix
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expected to be seen at age 1 year. For either maternal 
treatment, assuming no interaction between treatments, 
this number would give 80% power to detect rate ratios 
of 0·82 for malaria, 0·91 for diarrhoea, and 0·76 for 
pneumonia, with p values of less than 0·05, assuming 
frequency of disease in the placebo groups to be 50 per 
100 person-years for malaria,33 190 per 100 person-years 
for diarrhoea,34 and 25 per 100 person-years for 
pneumonia.35 Incidence of both tuberculosis and 
measles was expected to be low,18 therefore only very 
large diﬀ erences in incidence would be detected. 
Samples from 1594 infants assessed at 1 year would 
detect diﬀ erences in infant cytokine responses of 
0·11 log10 between intervention groups.18,32
The patients that were included in analysis for each of 
the primary outcomes diﬀ ered because data for each 
outcome was obtained at diﬀ erent times. For immune 
response at age 1 year, analysis included all children who 
provided a blood sample at 1 year and who had received 
full BCG (for cCFP analysis) or tetanus (for tetanus toxoid 
analysis) immunisation at Entebbe Hospital; second-born 
twins were excluded. For incidence of infectious diseases 
during infancy, analysis included all liveborn children, 
excluding second-born twins. For vertical HIV 
11 783 assessed for eligibility
2515 randomised
6243 not resident in Entebbe/Katabi
1186 unwilling to receive HIV result
874 unwilling to participate
646 incomplete screening procedures
115 already had baby in study
83 pregnancy not normal 
37 not planning to deliver in hospital 
17 haemoglobin <80 g/L
15 diarrhoea with blood in stool 
5 adverse reaction to anthelmintics
0 clinically apparent severe liver disease
47 other or no reason stated 
Allocation
Baseline
Birth
Analysis at 1 year
0 double enrolment 
628 allocated to
praziquantel
and albendazole
591 deliveries 
599 births 
12 stillbirths 
587 livebirths 
581 analysed for illness
episodes
427 analysed at 1 year
628 baseline group 
2 haemoglobin 
<80 g/L  
31 lost to follow-up 
before delivery 
4 miscarriages 
6 younger twins 
excluded from 
analyses
58 died or lost to 
follow-up before 
1 year
98 still in follow-up 
but did not attend 
1 year visit 
2 double enrolment 
628 allocated to praziquantel and 
albendazole-matching placebo
587 deliveries 
596 births 
13 stillbirths 
583 livebirths 
574 analysed for illness
episodes
420 analysed at 1 year
626 baseline group 
0 haemoglobin 
<80 g/L 
35 lost to follow-up 
before delivery 
4 miscarriages 
9 younger twins 
excluded from 
analyses
56 died or lost to 
follow-up before 
1 year
100 still in follow-up 
but did not attend 
1 year visit 
4 double enrolment 
629 allocated to albendazole and 
praziquantel-matching placebo
585 deliveries 
594 births 
11 stillbirths 
583 livebirths 
575 analysed for illness
episodes
432 analysed at 1 year
625 baseline group 
0 haemoglobin 
<80 g/L
34 lost to follow-up 
before delivery 
6 miscarriages 
8 younger twins 
excluded from 
analyses
47 died or lost to 
follow-up before 
1 year
99 still in follow-up 
but did not attend 
1 year visit 
2 double enrolment 
630 allocated to the two
placebo only
593 deliveries 
600 births 
8 stillbirths 
592 livebirths 
585 analysed for illness
episodes
422 analysed at 1 year
628 baseline group 
0 haemoglobin 
<80 g/L 
31 lost to follow-up 
before delivery 
4 miscarriages 
7 younger twins 
excluded from 
analyses
69 died or lost to 
follow-up before 
1 year
96 still in follow-up 
but did not attend 
1 year visit 
Figure: Trial proﬁ le
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transmission, analysis included all children whose 
mothers were not receiving highly-active antiretroviral 
therapy, and from whom blood samples at age 6 weeks 
were available; second-born twins were excluded. 
Cytokine and antibody responses showed skewed 
distributions, with disproportionate numbers of zero 
values. Results were transformed to log10(concentration+1) 
and analysed by linear regression with bootstrapping to 
estimate bias-corrected accelerated conﬁ dence intervals.36 
Regression coeﬃ  cients were back-transformed to give 
geometric mean ratios. Interactions were examined with 
Wald tests.
For doctor-diagnosed disease incidence, time at risk 
began at birth and was censored at loss to follow-up, death, 
or age 1 year. All children with known date of birth were 
included in the analysis until censoring, irrespective of 
whether they had made a clinic visit for illness. For each 
disease, we calculated incidence rates for all events. 
Disease episodes within 14 days of an initial presentation 
with the same disease were regarded as part of the same 
episode and excluded from the analysis; time at risk was 
adjusted accordingly, excluding these 14-day periods from 
the total person-time denominator. Hazard ratios (HRs) 
for eﬀ ects of treatment were calculated with Cox regression, 
with robust SEs to allow for within-child clustering. For 
community-reported illness data, a generalised-estimating-
equation approach with exchangeable correlation structure 
was used to model eﬀ ects of treatment on repeated binary 
outcomes. Odds ratios (ORs) for the eﬀ ects of treatment 
on vertical HIV transmission were calculated with logistic 
regression.
The prevalence of asymptomatic malaria at 1 year was 
compared between treatment groups with logistic 
regression. Infant mortality per 1000 livebirths was 
estimated from Kaplan-Meier survival probabilities to age 
1 year, and eﬀ ects of maternal anthelmintic treatment were 
assessed by Cox regression. Weight-for-age, height-for-age, 
and weight-for-height Z scores at 1 year were derived from 
WHO growth standard reference scales, with igrowup 
macros. We examined eﬀ ects of maternal treatment on 
Z scores and on haemoglobin at 1 year by linear 
regression.
We did two prespeciﬁ ed subgroup analyses, examining 
eﬀ ects of albendazole treatment in children of mothers 
with a hookworm infection, and eﬀ ects of praziquantel 
treatment in children of mothers with schistosomiasis. 
Diﬀ erences between subgroups were examined by ﬁ tting 
interaction terms in regression models. All p values were 
two-sided with no adjustment made for multiple 
comparisons. Analyses were done with Stata 10.1.
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. AME had full access to all the data in the study 
and had ﬁ nal responsibility for the decision to submit for 
publication.
Results
The ﬁ gure shows the trial proﬁ le. 2507 women were 
randomly assigned to treatment groups, 1309 (52%) of 
whom were in the second trimester of pregnancy and 
1195 (48%) of whom were in the third trimester of 
pregnancy. The median length of time between receiving 
the study intervention and delivery was 87 days 
(IQR 54–118). Data were available for 2356 women (94%) 
at delivery and there were 2345 livebirths; results for 
30 liveborn younger twins or triplets were excluded, which 
left data for follow-up of 2315 liveborn infants. Of these 
infants, 2092 (90%) remained in follow-up at 1 year of age, 
of whom 1701 (81%) attended the 1-year visit. Baseline 
characteristics of mothers were similar between the four 
groups (table 1).37 Mothers of children who did not 
contribute to follow-up were, on average, younger, more 
likely to be pregnant for the ﬁ rst time, have malaria or 
HIV infection, and have enrolled earlier during pregnancy 
than mothers of children who contributed to follow up 
(data not shown). Mothers of children who provided 
samples at 1 year of age were of higher socioeconomic 
status and less likely to reside in remote parts of the study 
area than were mothers of children who did not provide 
samples at age 1 year (data not shown).
At enrolment, 1693 (68%) of women were infected with 
at least one helminth species. Individual prevalences of 
each species were: hookworm 45%, M perstans 21%, 
S mansoni 18%, S stercoralis 12%, Trichuris trichiura 9%, 
and Ascaris lumbricoides 2%. Infections were generally 
mild, with 942 (85%) of hookworm infections and 
297 (65%) of S mansoni infections classiﬁ ed as light. 
Subgroups of 648 mothers who received albendazole-
matching placebo and 658 mothers who received 
praziquantel-matching placebo had three stool samples 
examined before being treated 6 weeks after delivery; in 
these women, the sensitivity of one stool sample compared 
with three stool samples was 89% for hookworm infection 
and 66% for schistosomiasis. 1957 mothers (78%) received 
at least one documented  dose of tetanus immunisation 
during pregnancy; 1447 (74%) received all documented 
tetanus immun isations before the anthelmintic treatment 
inter vention (median 4 days [IQR 3–7] before 
intervention). 
We noted no evidence of interaction between maternal 
albendazole and praziquantel treatments for any outcome 
(all interaction p values>0·1; webappendix pp 3–4); 
therefore the eﬀ ects of each treatment were assessed 
independently. Results for cytokine responses at age 1 year 
were available for 1542 infants, of whom 1506 had received 
BCG immunisation at birth at Entebbe Hospital and 
1015 had received all three doses of tetanus immunisation 
at Entebbe Hospital. The proportion of infants for whom 
positive responses to cCFP and tetanus toxoid were 
detected varied by cytokine; for cCFP, 1356 (90%) infants 
had positive responses to interferon-γ, 449 (30%) 
had positive responses to interleukin 5, 1005 (67%) had 
positive responses to interleukin 13, and 1316 (87%) 
For more on igrowup macros 
see http://www.who.int/
childgrowth/software/en/
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had positive responses to interleukin-10. For tetanus 
toxoid, 655 (65%) infants had positive responses 
to interferon-γ, 499 (49%) had positive responses to 
interleukin 5, 766 (75%) had positive responses 
to interleukin 13, and 498 (49%) had positive responses to 
interleukin 10.
Albendazole treatment of mothers was associated with 
a small reduction in unstimulated interleukin-10 
production by their children (geometric mean ratio 0·83, 
95% CI 0·70–0·98). We recorded no other overall eﬀ ects 
of maternal treatment on unstimulated cytokine 
production. Results for eﬀ ects on responses to stimulation 
were similar, irrespective of whether background cytokine 
production was subtracted (data not shown).
We detected no eﬀ ects of either albendazole or 
praziquantel treatments on the overall antigen-speciﬁ c 
response after immunisation (table 2). However, in 
infants of mothers with a hookworm infection, maternal 
albendazole treatment was associated with a small non-
signiﬁ cant reduction in the interferon-γ response to 
cCFP and with reductions in their response to tetanus 
toxoid for the type 2 cytokines interleukin 5 and 
interleukin 13 (table 3). We recorded no signiﬁ cant eﬀ ect 
of praziquantel treatment in infants of mothers with 
schistosomiasis (table 3).
We recorded no overall eﬀ ects for either albendazole or 
praziquantel treatments on antibody concentrations for 
tetanus or measles (table 2), nor did we detect diﬀ erential 
eﬀ ects for either albendazole or praziquantel treatment 
according to susceptible worm species (table 3). 
Of the 2315 liveborn children, 2083 (90%) made at 
least one illness-related clinic visit during infancy. The 
number of illness visits by children in all four treatment 
groups were similar (webappendix p 4). During the study 
period, the rate of malaria was 41 episodes per 100 person-
years (95% CI 38–44), of diarrhoea 134 episodes per 
100 person-years (129–139), and of pneumonia 
22 episodes per 100 person-years (20–24). Measles and 
tuberculosis were rare, with two episodes of each, so we 
could not assess the eﬀ ect of maternal anthelmintic 
treatment on their frequency.
We noted no evidence for eﬀ ects of either albendazole 
or praziquantel treatments on doctor-diagnosed malaria, 
diarrhoea, or pneumonia incidence (table 4). Subgroup 
analyses by maternal hookworm and schistosomiasis 
infection status showed no evidence of a diﬀ erential 
eﬀ ect of either treatment according to susceptible worm 
species (table 5).
299 women tested positive for HIV at enrolment; of 
these, 16 were lost to follow-up before delivery, ﬁ ve had 
miscarriages, and nine had stillbirths. Five women were 
on highly-active antiretroviral therapy; their children, and 
seven second-born twins were excluded from the analysis, 
leaving 264 infants suitable for inclusion. 6-week blood 
samples were available from 211 infants (80%), of 
whom 39 (18%) were diagnosed with HIV infection. Of 
infants with HIV infection, 31 had cord samples available, 
of which 20 (65%) showed an HIV viral load of 1000 copies 
per mL or more, which is consistent with intrauterine 
HIV transmission. We recorded no evidence for any 
eﬀ ect of either albendazole (OR 0·70, 95% CI 0·35–1·42; 
p=0·33) or praziquantel (0·60, 0·29–1·23; p=0·17) 
treatment on vertical HIV transmission, although 
statistical power was restricted because the study was 
only powered to detect a large eﬀ ect for this outcome. No 
Albendazole+ 
praziquantel (n=628) 
Praziquantel 
only (n=626)
Albendazole 
only (n=625)
Placebo 
(n=628)
Age (years) 
<20 145 (23%) 165 (26%) 162 (26%) 158 (25%)
20–24 223 (36%) 230 (37%) 238 (38%) 255 (41%)
25–29 159 (25%) 143 (23%) 139 (22%) 122 (19%)
30–34 66 (11%) 62 (10%) 55 (9%) 70 (11%)
≥35 35 (6%) 26 (4%) 31 (5%) 23 (4%)
Education (4 missing values)
None 25 (4%) 23 (4%) 17 (3%) 32 (5%)
Primary 311 (50%) 318 (51%) 318 (51%) 316 (50%)
Secondary 235 (37%) 229 (37%) 244 (39%) 226 (36%)
Tertiary 56 (9%) 55 (9%) 45 (7%) 53 (8%)
Tribe (1 missing value)
Baganda 303 (48%) 314 (50%) 313 (50%) 301 (48%)
Banyankole 64 (10%) 47 (8%) 56 (9%) 67 (11%)
Batoro 19 (3%) 27 (4%) 24 (4%) 32 (5%)
Basoga 36 (6%) 23 (4%) 27 (4%) 20 (3%)
Luo 32 (5%) 41 (7%) 30 (5%) 37 (6%)
Banyarwanda 38 (6%) 36 (6%) 31 (5%) 37 (6%)
Others 136 (22%) 138 (22%) 144 (23%) 133 (21%)
Household socioeconomic status (49 missing values)*
1 (low) 33 (5%) 40 (7%) 35 (6%) 39 (6%)
2 54 (9%) 57 (9%) 54 (9%) 52 (8%)
3 190 (31%) 199 (33%) 182 (30%) 194 (32%)
4 174 (28%) 174 (28%) 179 (29%) 183 (30%)
5 130 (21%) 109 (18%) 131 (21%) 115 (19%)
6 (high) 37 (6%) 32 (5%) 33 (5%) 32 (5%)
Gravidity 
1 178 (28%) 172 (27%) 181 (29%) 164 (26%)
2–4 339 (54%) 354 (57%) 350 (56%) 369 (59%)
≥5 111 (18%) 100 (16%) 94 (15%) 95 (15%)
Helminth infections
Hookworm
(11 missing values)
270 (43%) 301 (48%) 262 (42%) 277 (44%)
Schistosoma mansoni
(11 missing values)
117 (19%) 104 (17%) 123 (20%) 114 (18%)
Mansonella perstans
(8 missing values)
135 (22%) 136 (22%) 117 (19%) 143 (23%)
HIV status
Positive 79 (13%) 61 (10%) 71 (11%) 88 (14%)
Malaria parasitaemia (48 missing values) 
Positive 61 (10%) 59 (10%) 63 (10%) 85 (14%)
Data have been previously reported by Ndibazza and colleagues.37 *Household socioeconomic status was scored on the 
basis of building materials of the home, number of rooms, and items owned.
Table 1: Baseline characteristics
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Geometric mean* Geometric mean ratio (95% CI)† Geometric mean* Geometric mean ratio (95% CI)†
Albendazole Placebo Praziquantel Placebo
Cytokine responses
cCFP‡ 
Interferon-γ (pg/mL) 322 313 1·03 (0·83–1·27) 320 314 1·02 (0·82–1·26)
Interleukin 5 (pg/mL) 3·5 3·8 0·91 (0·74–1·11) 3·6 3·7 0·95 (0·78–1·17)
Interleukin 13 (pg/mL) 17 18 0·95 (0·77–1·18) 18 17 1·05 (0·84–1·30)
Interleukin 10 (pg/mL) 90 102 0·88 (0·73–1·06) 98 95 1·03 (0·85–1·24)
Tetanus toxoid§
Interferon-γ (pg/mL) 31 36 0·85 (0·61–1·20) 34 33 1·03 (0·75–1·44)
Interleukin 5 (pg/mL) 10 13 0·76 (0·56–1·04) 11 11 0·93 (0·68–1·27)
Interleukin 13 (pg/mL) 40 41 0·97 (0·73–1·27) 37 44 0·84 (0·63–1·12)
Interleukin 10 (pg/mL) 4·7 5·9 0·79 (0·61–1·02) 5·0 5·6 0·89 (0·69–1·16)
Antibody concentrations
Tetanus toxoid¶
Total IgG (mIU/mL) 160 251 0·64 (0·39–1·05) 227 176 1·32 (0·78–2·12)
IgG4 (ng/mL) 50 69 0·72 (0·37–1·37) 48 71 0·68 (0·36–1·29)
IgE (ng/mL) 1389 1507 0·92 (0·76–1·11) 1460 1430 1·02 (0·85–1·24)
Measles||
Total IgG (mIU/mL) 336 348 0·96 (0·85–1·10) 332 353 0·94 (0·83–1·07)
cCFP=crude culture ﬁ ltrate proteins of Mycobacterium tuberculosis. *Geometric mean of response concentration + 1. † Bias-corrected accelerated CIs computed by 
bootstrapping. ‡cCFP cytokine responses were available for 1506 infants given BCG at Entebbe hospital. §Tetanus toxoid cytokine results were available for 1015 infants who 
received all three doses of tetanus toxoid; one missing value for interferon-γ response. ¶ Tetanus toxoid antibody results were available for 1058 (IgG), 1057 (IgG4), and 
979 (IgE) infants who received all three doses of tetanus toxoid. || Measles antibody results were available for 1233 infants who received measles immunisation.
Table 2: Eﬀ ects of maternal anthelmintic treatment in pregnancy on infant response to BCG, tetanus, and measles immunisation
Albendazole Praziquantel
Eﬀ ect of treatment in 
women with hookworm 
infection (GMR, 95% CI)
Eﬀ ect of treatment in 
women without 
hookworm infection 
(GMR, 95% CI)
p value for 
interaction
Eﬀ ect of treatment in 
women with 
schistosomiasis 
(GMR, 95% CI)
Eﬀ ect of treatment in 
women without 
schistosomiasis 
(GMR, 95% CI)
p value for 
interaction
cCFP*
Interferon-γ 0·73 (0·52–1·02) 1·31 (1·00–1·74) 0·009 0·88 (0·50–1·56) 1·05 (0·83–1·33) 0·56
Interleukin 5 1·06 (0·78–1·44) 0·82 (0·62–1·08) 0·22 1·20 (0·75–1·87) 0·91 (0·73–1·15) 0·30
Interleukin 13 0·96 (0·69–1·32) 0·95 (0·70–1·26) 0·97 1·07 (0·64–1·80) 1·04 (0·82–1·32) 0·92
Interleukin 10 0·93 (0·70–1·26) 0·85 (0·66–1·08) 0·62 1·14 (0·68–1·92) 1·00 (0·82–1·22) 0·65
Tetanus toxoid†
Interferon–γ 0·61 (0·36–1·05) 1·08 (0·71–1·66) 0·10 0·71 (0·32–1·60) 1·11 (0·78–1·60) 0·32
Interleukin 5 0·50 (0·30–0·81) 1·02 (0·68–1·52) 0·02 0·60 (0·30–1·28) 1·02 (0·72–1·43) 0·19
Interleukin 13 0·52 (0·34–0·82) 1·45 (1·02–2·10) 0·0005 0·56 (0·28–1·09) 0·92 (0·68–1·25) 0·18
Interleukin 10 0·74 (0·48–1·13) 0·83 (0·59–1·16) 0·68 0·94 (0·52–1·71) 0·89 (0·66–1·18) 0·86
Tetanus toxoid‡
Total IgG 0·52 (0·24–1·16) 0·74 (0·39–1·42) 0·51 0·72 (0·22–2·40) 1·43 (0·83–2·49) 0·30
IgG4 0·71 (0·25–1·96) 0·74 (0·31–1·71) 0·95 0·51 (0·10–2·56) 0·71 (0·36–1·45) 0·72
IgE 0·93 (0·69–1·25) 0·92 (0·71–1·16) 0·95 0·70 (0·45–1·17) 1·10 (0·90–1·36) 0·09
Measles§
Total IgG 1·02 (0·83–1·26) 0·93 (0·79–1·09) 0·51 0·92 (0·69–1·24) 0·94 (0·82–1·08) 0·88
cCFP=crude culture ﬁ ltrate proteins of Mycobacterium tuberculosis. GMR=geometric mean ratio. *cCFP cytokine responses were available for 1506 infants given BCG at 
Entebbe Hospital; four missing values in this analysis for infants of women with no stool result for Kato-Katz analysis. †Tetanus toxoid cytokine results were available for 
1015 infants who received all three doses of tetanus toxoid; two missing values in this analysis for infants of women with no stool result for Kato-Katz analysis; one missing 
value for interferon-γ response to tetanus toxoid. ‡Tetanus toxoid antibody results were available for 1058 (IgG), 1057 (IgG4), and 979 (IgE) infants who received all three 
doses of tetanus toxoid; one missing value in this analysis for an infant of a woman with no stool result for Kato-Katz analysis. § Measles antibody results were available for 
1233 infants who received measles immunisation; three missing values in this analysis for infants of women with no stool result for Kato-Katz analysis.
Table 3: Eﬀ ect of maternal anthelmintic treatment on response to BCG, tetanus, and measles immunisation, by maternal helminth infection status
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evidence was noted for any diﬀ erential eﬀ ect of treatment 
according to susceptible worm species; ORs for the eﬀ ect 
of albendazole treatment on HIV transmission were 
0·77 (0·25–2·40) in mothers with hookworm infection 
and 0·66 (0·27–1·60) in those without hookworm 
infection (interaction p=0·83). We recorded similar 
results for praziquantel (OR 0·75, 0·18–3·14, for mothers 
with schistosomiasis; 0·56, 0·24–1·29 for those without 
schistosomiasis; interaction p=0·73).
For the secondary outcome of community-reported 
illness data, the overall recorded prevalences of each 
illness collated every 14 days throughout infancy was 13% 
for febrile illness, 12% for diarrhoea, and 1% for 
presumptive pneumonia. These data were consistent 
with doctor-diagnosed outcomes and showed no eﬀ ects 
of treatment with albendazole or praziquantel on febrile 
illnesses (OR 1·07, 95% CI 0·97–1·18, p=0·18; and 1·03, 
0·93–1·13, 0·58), diarrhoea (1·08, 0·98–1·20, 0·13; and 
0·93, 0·84–1·03, 0·18), or presumptive pneumonia 
(0·92, 0·65–1·31, 0·66; and 0·91, 0·64–1·30, 0·62). The 
prevalence of asymptomatic malaria parasitaemia at 
1 year was similar between treatment groups 
(webappendix p 5).
81 infants in the cohort died, 44 of whom were neonates, 
giving a neonatal mortality rate of 19·0 per 1000 livebirths 
(95% CI 14·2–25·5) and an infant mortality rate of 
35·7 per 1000 livebirths (28·8–44·2). Maternal 
anthelmintic treatment had no pronounced eﬀ ect on 
mortality (webappendix p 5). Height-for-age and weight-
for-age Z scores were low compared with the WHO 
standards; however, the weight-for-height distribution 
was similar. Mean haemoglobin score at age 1 year was 
102 g/L (SD 14 g/L). We noted no evidence  for any 
diﬀ erence in mean growth indices or mean haemoglobin 
between children of albendazole-treated and placebo-
treated mothers, or between children of praziquantel-
treated and placebo-treated mothers (webappendix p 5). 
Numbers of serious adverse events are reported 
elsewhere19 and were distributed evenly between 
treatment groups.
Discussion
In this randomised, placebo-controlled trial, we have 
shown that maternal anthelmintic treatment during 
pregnancy can have a small eﬀ ect on an infant’s response 
to tetanus immunisation, but has no eﬀ ects, either 
beneﬁ cial or detrimental, on the occurrence of infectious 
diseases during infancy, infant mortality, or growth and 
anaemia outcomes at 1 year of age. One dose of 
albendazole was eﬀ ective for the treatment of hookworm 
and A lumbricoides infections, and praziquantel was 
eﬀ ective for the treatment of schistosomiasis. At delivery, 
the prevalence of hookworm infections had decreased to 
5% in the albendazole group, and remained at 45% in the 
placebo group; the prevalence of S mansoni infection had 
decreased to 5% in the praziquantel group, and remained 
at 21% in the placebo group.37 Thus we would have 
expected to see any noticeable eﬀ ects of the removal of 
these maternal helminth infections. A possible source of 
imprecision is that the Kato-Katz method has suboptimum 
Albendazole Albendazole-matching 
placebo
HR 
(95% CI)*
p value* Praziquantel Praziquantel-matching 
placebo
HR 
(95% CI)†
p value†
Events 
(person-years)
Rate per 
100 person-
years (95% CI)
Events 
(person-
years)
Rate per 
100 person-
years (95% CI)
Events 
(person–
years)
Rate per 
100 person–
years (95% CI)
Events 
(person–
years)
Rate per 
100 person–
years (95% CI)
Malaria 431 (1081) 39·9 
(36·3–43·8)
446 (1062) 42·0 
(38·3–46·1)
0·95 
(0·79–1·14)
0·56 440 (1073) 41·0 
(37·3–45·0)
437 (1070)      40·9 
(37·2–44·9)
1·00 
(0·84–1·20)
0·97
Diarrhoea 1438 (1043) 137·9 
(131·0–145·3)
1339 (1029) 130·2 
(123·4–137·3)
1·06 
(0·96–1·16)
0·24 1437 (1036) 138·7 
(131·7–146·1)
1340 (1035) 129·4 
(122·7–136·6)
1·07 
(0·98–1·18)
0·15
Pneumonia 256 (1087) 23·5 
(20·8–26·6)
226 (1070) 21·1 
(18·5–24·1)
1·11 
(0·90–1·38)
0·33 241 (1081) 22·3 
(19·7–25·3)
241 (1077) 22·4 
(19·7–25·4)
1·00 
(0·80–1·24)
0·97
HR=hazard ratio. *Between albendazole and albendazole-matching placebo. †Between praziquantel and praziquantel-matching placebo.
Table 4: Eﬀ ects of maternal anthelmintic treatment in pregnancy on incidence of malaria, diarrhoea, and pneumonia in infancy
Albendazole Praziquantel
Eﬀ ect of treatment in women 
with hookworm infection 
HR (95% CI)
Eﬀ ect of treatment in women 
without hookworm infection 
HR (95% CI)
p value for 
interaction
Eﬀ ect of treatment in women 
with schistosomiasis HR (95% CI)
Eﬀ ect of treatment in women 
without schistosomiasis 
HR (95% CI)
p value for 
interaction
Malaria* 1·01 (0·78–1·31) 0·89 (0·69–1·15) 0·48 0·94 (0·62–1·41) 1·03 (0·84–1·26) 0·70
Diarrhoea* 1·10 (0·95–1·27) 1·02 (0·90–1·16) 0·44 1·23 (0·99–1·54) 1·05 (0·94–1·16) 0·18
Pneumonia* 1·08 (0·77–1·53) 1·12 (0·85–1·48) 0·88 0·94 (0·61–1·45) 1·01 (0·79–1·30) 0·79
HR=hazard ratio. *Excludes nine women with no stool result for Kato-Katz analysis.
Table 5: Eﬀ ect of maternal anthelmintic treatment in pregnancy on disease incidence, by maternal helminth status
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sensitivity for diagnosis of intestinal helminth infections 
when one stool sample is used.38,39 In this study, the 
sensitivity for detecting both hookworm infection and 
schistosomiasis was greater when three stool samples 
were taken than when only one was taken. As expected, 
one dose of albendazole was not eﬀ ective for treatment of 
S stercoralis, T trichiura, or M perstans.37
Albendazole treatment in pregnancy was associated 
with reduced interleukin-5 and interleukin-13 responses 
to tetanus toxoid in infants of mothers with hookworm 
infection. These results should be interpreted with 
caution because of the large number of statistical tests 
done, but they accord with earlier ﬁ ndings40,41 on eﬀ ects 
of helminths on type-2 responses to tetanus immunisation 
in adults; by contrast with these previous studies,40,41 we 
recorded no reciprocal eﬀ ect on interferon-γ response. 
Such responses will probably not change the eﬀ ectiveness 
of tetanus immunisation, because this immunisation 
depends on the production of toxin-neutralising 
IgG antibodies, which was not aﬀ ected by maternal 
treatment. However, the patterns recorded lend support 
to the hypothesis that maternal helminths promote a 
type-2 bias in an infant’s response to unrelated antigens 
and that anthelmintic treatment modiﬁ es this eﬀ ect. 
These ﬁ ndings suggest that the eﬀ ect of anthelmintic 
treatment can be transmitted in utero.
Neither intervention showed any overall eﬀ ect on 
response to BCG immunisation in infants. Our 
preliminary study32 had suggested an unexpected positive 
association between maternal hookworm infection and 
interferon-γ responses to cCFP in infants. In the present, 
larger study, interferon-γ responses were higher in 
infants of mothers with hookworm infection, and 
albendazole treatment was associated with a weak 
reduction in interferon-γ responses in infants of women 
with hookworm infection. These ﬁ ndings contrast with 
our initial hypothesis that maternal hookworm infection 
would inhibit the Th1 response and that albendazole 
treatment would reverse this eﬀ ect. The absence of eﬀ ect 
of praziquantel treatment was also unexpected, in view of 
Malhotra and colleagues’ ﬁ nding17 that infants who are 
sensitised to schistosome or ﬁ larial antigens in utero had 
reduced interferon-γ and increased interleukin-5 
responses to neonatal BCG immunisation. However, all 
infants in Malhotra and colleagues’ study were exposed 
to maternal helminth infections, and comparisons were 
made between those not sensitised or sensitised to 
helminth antigens.17 The idea that single-dose 
praziquantel treatment completely removes the likelihood 
of fetal sensitisation to schistosome antigens might be 
too simplistic, because worm and egg antigens can take 
some time to be cleared from maternal tissues. Moreover, 
the killing of adult schistosomes results in release of 
worm antigen into the circulation and might have 
complex eﬀ ects on the fetus, dependent on placental 
transfer of antigens or antibodies and the stage of 
development of the fetal immune system.41,42
The recorded eﬀ ects on an infant’s response to tetanus 
immunisation contrasted with the absence of eﬀ ects 
seen for measles and BCG. A possible explanation is 
that tetanus immunisation given to women during 
pregnancy could have led to the priming of an infant’s 
antitetanus response in utero,42 and the proﬁ le of the 
primed response could have been aﬀ ected by 
concomitant exposure to a maternal helminth infection, 
which depended on whether or not an infant’s mother 
received treatment with albendazole.
In keeping with the broad absence of eﬀ ect of maternal 
anthelmintic treatment on an infant’s response to 
vaccination, we recorded no eﬀ ect of either treatment for 
the co-primary outcome of infectious disease incidence 
during infancy. A possible source of imprecision is that 
data for doctor-diagnosed disease incidence were 
obtained passively, and therefore rates are likely to have 
been underestimated. However, 90% of infants attended 
the clinic for illness at least once, and underestimation 
would be non-diﬀ erential between treatment groups; 
therefore this imprecision is unlikely to have aﬀ ected 
our ﬁ ndings. Moreover, results from community-
reported illness events (which are less likely to be under-
reported), and malaria parasitaemia at 1 year of age 
(which is independent of reporting biases) were both 
consistent with the recorded absence of treatment eﬀ ect. 
We also detected no evidence that anthelmintic treatment 
aﬀ ected vertical transmission of HIV, although power to 
detect an eﬀ ect was restricted.
The only other study43 to investigate the relation 
between anthelmintic treatment during pregnancy and 
post-neonatal outcomes, undertaken in Nepal, showed 
that treatment with albendazole during pregnancy was 
associated with a pronounced reduction in infant 
mortality at 6 months. We recorded no such eﬀ ect, 
although the number of deaths in the cohort was small 
so the possibility of a reduction cannot be ruled out. The 
Nepal study was not randomised and recorded a 41% 
reduction in 6-month mortality associated with two doses 
of albendazole but no eﬀ ect on infant mortality for one 
dose. The researchers speculated that the greater beneﬁ t 
of two doses might result from prevention of reinfection 
between treatment and delivery, but this theory would 
not explain the contrast with our ﬁ ndings, because only 
5% of women who received albendazole in our study had 
hookworm infection at delivery.19
Our analyses needed many statistical tests, especially for 
the measurement of cytokine responses to immunisation, 
because we aimed to assess overall response proﬁ les 
rather than concentrations of only one cytokine. 
Consistency between all cytokine responses was expected, 
and can be interpreted as compelling evidence of an eﬀ ect, 
compared with isolated change in an individual response. 
Therefore we did not increase conﬁ dence limits or use 
methods that assume independence of tests to formally 
adjust p values. In the event, very few outcomes showed 
any evidence of association at a p value less than 0·05 so 
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absence of adjustment for multiplicity is unlikely to have 
aﬀ ected the interpretation of our results.
A strength of this study was the randomised intervention 
design; eﬀ ects of helminth infections reported in 
observational studies could have been aﬀ ected by 
confounding factors. Our ﬁ ndings do not show that 
exposure to maternal helminth infections in utero has no 
important eﬀ ect on the development of the fetal immune 
system. Some observational studies16,17 do suggest such an 
eﬀ ect. Rather, our ﬁ ndings suggest that one eﬀ ective 
anthelmintic intervention given in the second or third 
trimester of pregnancy is insuﬃ  cient to alter any eﬀ ect of 
maternal worms on vaccine and infectious disease 
outcomes in infancy. This study examined only eﬀ ects of 
maternal anthelmintic treatment on vaccine responses 
and disease incidence in newborn children. Further 
studies are needed to assess the eﬀ ects of anthelmintic 
treatment on these outcomes in the individual who 
receives the treatment.
Our results are generalisable to areas with high 
prevalence but low intensity of helminth infection in 
young adults, which is a common pattern in areas that 
are endemic for helminth infection. Findings might 
diﬀ er in populations with higher infection intensities. 
These results suggest that, in settings such as Entebbe 
Municipality and Katabi subcounty, single-dose 
anthelmintic treatment during pregnancy has no beneﬁ t 
for an infant’s response to immunisation, or for their 
health and development. 
We have previously reported a similar absence of eﬀ ect 
on maternal and perinatal outcomes.37 These results 
contrast with the expected beneﬁ ts of routine antenatal 
anthelmintic treatment recently advocated,44 and the 
value of such a policy may need to be reviewed. The study 
cohort is being followed up to establish whether these 
conclusions are still valid up to when children are aged 
5 years, and to relate eﬀ ects on the cytokine response to 
BCG immunisation to incidence of M tuberculosis 
infection and disease.18
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